Pfizer releases SUTENT trial results

Pfizer has released results from its Phase 3 S-TRAC clinical study involving the assessment of SUTENT as an adjuvant therapy.

Compared to placebo, SUTENT prolonged disease-free survival (DFS) for over a year.

“We are encouraged by the S-TRAC results because this is the first clinical trial to show increased disease-free survival in the adjuvant setting for RCC,” lead investigator Dr. Alain Ravaud said. “These data are promising for RCC patients as there are no effective treatments currently available in this setting.”

Adjuvant therapies used to decrease the chance of cancer returning post-surgery.

“For the past 10 years, Pfizer has been a leader in developing new treatments for patients with kidney cancer, and SUTENT has been the most widely prescribed first line treatment for thousands of patients with advanced RCC around the world,” Dr. Mace Rothenberg, Pfizer Global Product Development's chief development officer for oncology, said. “The results of S-TRAC suggest that SUTENT has the potential to extend this benefit by reducing the risk of recurrence in patients who have undergone complete surgical removal of their kidney cancer and are at high risk of cancer recurrence.”